Stanley Oyaghire

Stanley Oyaghire is a Senior Scientist at CRISPR Therapeutics since January 2020, where contributions include authoring the Quality sections of INDs and CTAs for CTX112™ and CTX131™ and leading a team to complete an assay qualification package. Prior experience includes roles as Scientist II and Scientist I at CRISPR Therapeutics, overseeing analytical tech transfer and developing release assays for CTX001 (now exa-cel®). Stanley completed a Postdoctoral Fellowship at Yale University School of Medicine, focusing on peptide nucleic acid oligomers for gene editing, and earned a Ph.D. in Chemistry from Carnegie Mellon University, where novel spectroscopic methods and peptide nucleic acid ligands were developed. Early research assistant roles at Morgan State University and Texas A&M University contributed to significant advancements and funding in dye synthesis and peptide mimic optimization.